ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2009

Nov 24, 2009

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity LIVING CELL TECHNOLOGIES LTD ABN 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR ROBERT FINDER
Date of last notice	29 SEPTEMBER 2009

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct or indirect interest	Direct or indirect interest	INDIRECT	INDIRECT	INDIRECT	INDIRECT
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.				WIFE
	Date of change				19 NOVEMBER 2009
	No. of securities held prior to change				150,000 UNLISTED OPTIONS (HELD BYSHERYL JEAN FINDER), EXERCISE PRICE$0.25, VESTING DATE 23 SEPTMEBER2010, EXPIRY DATE 19 NOVEMBER 2014.(SUBJECTTOSHAREHOLDERAPPROVAL)250,000 UNLISTED OPTIONS (HELD BY
					SHERYL JEA$0.35, VEST2010 EXPIRY	FINDER), EXEING DATE 23DATE 19 NOV	RCISE PRICESEPTEMBEREMBER 2014.
					,(SUBJECT	TOSH	AREHOLDER
					APPROVAL)
ClaNu
	Cla	ss			UNLISTED O	PTIONS
	Nu	mber acquired			400,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Number disposed	NIL	NIL	NIL	NIL
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation		NIL ISSUE PRICE
	onsideration is non-cash, provide details and estimated
No. of securities held after change	curities held after change	150,000 UNLISTEDSHERYL JEAN FIND		OPTIONS (HELD BYR) EXERCISE PRICE
		$0.25, VESTING DA		,TE 23 SEPTMEBER
		2010, EXPIRY DATE		9 NOVEMBER 2014.
		250,000 UNLISTED OPTIONS (HELD BYSHERYL JEAN FINDER), EXERCISE PRICE$0.35, VESTING DATE 23 SEPTEMBER2010 EXPIRY DATE 19 NOVEMBER 2014.
			,
Nature oExample: osecurities un		IS	UEOFOPTION		APPROVEDBY
	f changen-market trade, off-market trade, exercise of options, issue ofder dividend reinvestment lan articiation in bu-back	SH	AREHOLDERS AT T		HE AGM HELD ON
	p, pp y	19	11/2009

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

	is part.	is part.
Detail of	contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of	change
No. andinterestNote: Detailto which the	class of securities to which
	related prior to changes are only required for a contract in relation
	interest has changed
Interest
	acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation
Interest	after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002